The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

by Liang Zhou, Yu Zhang, Yun Leng, Yun Dai, Maciej Kmieciak, Lora Kramer, Kanika Sharma, Yan Wang, William Craun, Steven Grant
Published 2019-03-01

Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

by Yun Leng, Lugui Qiu, Jian Hou, Yaozhong Zhao, Xuejun Zhang, Shifang Yang, Hao Xi, Zhongxia Huang, Ling Pan, Wenming Chen
Published 2016-09-01